Form 4: Ultragenyx Executive Receives Equity Compensation

Dennis Karl Huang, EVP and Chief Technical Operations Officer at Ultragenyx, was granted restricted stock units and stock options as part of the company's 2023 Incentive Plan.

Summary

• Dennis Karl Huang, EVP and Chief Technical Operations Officer, received an award of 23,116 Restricted Stock Units (RSUs).
• The reporting person was also granted stock options to purchase 79,936 shares of common stock at an exercise price of $24.52.
• The RSU grant vests over four years, with 25% vesting on each anniversary of the grant date.
• The stock options vest 25% on the first anniversary, with the remainder vesting monthly over the following three years.
• Following these transactions, the reporting person holds 147,845 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral for the stock price.

Positives

• Equity-based compensation aligns executive interests with long-term shareholder value creation.
• The multi-year vesting schedule encourages executive retention.

Negatives

• The issuance of new equity awards results in potential dilution for existing shareholders.

Risks

• Future share price volatility may impact the ultimate value realized by the executive from these equity grants.
• Vesting is subject to the executive's continued employment with the company.

Future Outlook

The equity grants are subject to standard vesting schedules over a four-year period, contingent upon continued service.

Management Comments

• The transactions were executed under the company's 2023 Incentive Plan.

Industry Context

StockSavvy.ai notes that equity-based compensation is standard practice in the biotechnology sector to attract and retain high-level technical and operational leadership.

Comparison to Industry Standards

• The use of a four-year vesting schedule for RSUs and options is consistent with standard corporate governance practices for executive compensation in the life sciences industry.
• The grant size is typical for an EVP-level role in a mid-cap pharmaceutical company.

Stakeholder Impact

• Shareholders may experience minor dilution from the issuance of new equity.

Next Steps

• Vesting of the first tranche of RSUs on 04/16/2027.
• Vesting of the first tranche of stock options on 04/16/2027.

Key Dates

Keywords

Ultragenyx, RARE, Form 4, Insider Trading, Equity Compensation, Biotech